Compare Aurora Cannabis Inc (ACB) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

IEFA trades at $98.31, up 1.04% with a bullish technical signal from moving averages. The ETF focuses on developed international markets excluding North America, offering diversification from US concentration risks. Recent news highlights strong performance comparisons against peers like VXUS and EEM, with a competitive 3.30% dividend yield and low 0.07% expense ratio. Central bank policy shifts in Europe and Japan present both opportunities and headwinds for international exposure.

The outlook remains positive given technical momentum and diversification benefits, though currency fluctuations and developed market monetary policy changes pose risks. Analyst sentiment leans bullish with the ETF positioned as a core holding for international diversification, but investors should monitor geopolitical developments and relative performance against US equities.